Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Assets: 2015-2025

Historic Assets for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to $143.5 million.

  • Seres Therapeutics' Assets fell 19.73% to $143.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $143.5 million, marking a year-over-year decrease of 19.73%. This contributed to the annual value of $139.8 million for FY2024, which is 61.01% down from last year.
  • Latest data reveals that Seres Therapeutics reported Assets of $143.5 million as of Q3 2025, which was down 0.23% from $143.8 million recorded in Q2 2025.
  • Over the past 5 years, Seres Therapeutics' Assets peaked at $406.4 million during Q2 2023, and registered a low of $139.8 million during Q4 2024.
  • For the 3-year period, Seres Therapeutics' Assets averaged around $257.8 million, with its median value being $270.2 million (2023).
  • Its Assets has fluctuated over the past 5 years, first skyrocketed by 176.35% in 2021, then slumped by 61.01% in 2024.
  • Over the past 5 years, Seres Therapeutics' Assets (Quarterly) stood at $354.9 million in 2021, then decreased by 1.71% to $348.8 million in 2022, then increased by 2.81% to $358.6 million in 2023, then crashed by 61.01% to $139.8 million in 2024, then declined by 19.73% to $143.5 million in 2025.
  • Its Assets stands at $143.5 million for Q3 2025, versus $143.8 million for Q2 2025 and $164.2 million for Q1 2025.